eTable 1. Measurement of adherence to medications.
| Adherence to | Studies with maximal follow-up period (method) |
|---|---|
| Measurement over frequencies | |
| Prescribed medications |
6-9 Months: e1 (MEMS), e2 (self-reporting), e3 (MEMS), e4 (self-reporting), e5 (MEMS) ≥ 12 Months: e6, e7-e12 (self-reporting), e13 (tablet accountability method), e14 (self-reporting), e15 (MEMS) |
| Beta-Blockers |
3 Months: e3 (MEMS) ≥ 12 Months: e12, e14, e16, e17 (self-reporting) |
| ACE-inhibitors / ARB |
3 Months : e3 (MEMS) 6-9 Months: e18 (self-reporting) ≥ 12 Months: e12, e14, e16, e19 (self-reporting) |
| Diuretica / spironolactone |
3 Months: e3 (MEMS) ≥ 12 Months: e12 (self-reporting) |
| MRA | ≥ 12 Months: e14 (self-reporting) |
| Furoseminide | ≥ 12 Months: e12 (self-reporting) |
| Measurement over scores | |
| Prescribed medications |
3 Months:
e20, e21 (self-reporting) 6-9 Months: e22 (MARS) ≥ 12 Months: e23 and e24, e25 (Morisky-Score), e26 (selfreporting) |
MARS, medication adherence record scale; MEMS, medication event monitoring; MRA, mineralocorticoid receptor antagonist